Humacyte Inc (NASDAQ: HUMA) on Friday, plunged -2.70% from the previous trading day, before settling in for the closing price of $1.48. Within the past 52 weeks, HUMA’s price has moved between $1.15 and $9.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 42.00%. With a float of $125.75 million, this company’s outstanding shares have now reached $130.03 million.
The extent of productivity of a business whose workforce counts for 220 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of -1582.71%, and the pretax margin is 0.0%.
Humacyte Inc (HUMA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 18.94%, while institutional ownership is 27.68%. The most recent insider transaction that took place on Apr 14 ’25, was worth 9,999. In this transaction Chief Commercial Officer of this company bought 6,493 shares at a rate of $1.54, taking the stock ownership to the 22,018 shares. Before that another transaction happened on Apr 10 ’25, when Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for $1.53, making the entire transaction worth $30,600. This insider now owns 40,600 shares in total.
Humacyte Inc (HUMA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.00% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 2.40 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.30 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
The latest stats from [Humacyte Inc, HUMA] show that its last 5-days average volume of 3.04 million was inferior to 3.4 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 32.38%. Additionally, its Average True Range was 0.20.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 5.16%, which indicates a significant decrease from 52.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 155.64% in the past 14 days, which was higher than the 124.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.5088, while its 200-day Moving Average is $4.7856. Now, the first resistance to watch is $1.4767. This is followed by the second major resistance level at $1.5133. The third major resistance level sits at $1.5467. If the price goes on to break the first support level at $1.4067, it is likely to go to the next support level at $1.3733. The third support level lies at $1.3367 if the price breaches the second support level.
Humacyte Inc (NASDAQ: HUMA) Key Stats
Market capitalization of the company is 223.37 million based on 155,119K outstanding shares. Right now, sales total 0 K and income totals -148,700 K. The company made 0 K in profit during its latest quarter, and -20,940 K in sales during its previous quarter.
